QC
KERX

QCM Cayman’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

QCM Cayman’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-35,423
Closed -$133K – 190
2018
Q2 		$133K Buy
+35,423
New +$172K 0.62% 66
2016
Q2 		– Sell
-10,185
Closed -$48K – 385
2016
Q1 		$48K Buy
+10,185
New +$40.6K 0.03% 186

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM Cayman's KERX Position: Q3 2018 in Review

QCM Cayman sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 35,423 shares — an estimated $133K sold.

QCM Cayman first reported a position in KERX in Q1 2016 and held it in 2 quarters. The position peaked at $133K in Q2 2018. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • QCM Cayman reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • QCM Cayman sold 35,423 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $133K.
  • QCM Cayman first reported a position in Keryx Biopharmaceuticals Inc in Q1 2016 and held it in 2 quarters.
  • QCM Cayman's Keryx Biopharmaceuticals Inc position peaked at $133K in Q2 2018.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on QCM Cayman's 13F filing for Q3 2018, filed 14 Nov 2018.